CD274 and cancer: Approaches, such as engineered PD-L1-expressing DC cells, or PD-L1 carrying adenovirus delivery into the kidney to tamp down immune activation in the region, may also be approaches of consideration However, they require precise delivery to the kidney, as the elevation of PD-L1, and the subsequent immunosuppression, may hinder concurrent cancer therapy [31].